Antioxidant treatment of tardive dyskinesia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 77-81

  Rotrosen, John ^a,b   Adler, Lenard ^a,b   Lohr, James ^a,c   Edson, Robert ^d   Lavori, Philip ^d,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Palo Alto Coop Studs Coord Center   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; FREE RADICAL; NEUROLEPTIC AGENT;

CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

EID: 0029759914     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90149-0     Document Type: Conference Paper

References (63)

1. Smith J. M., Kucharski L. T., Oswald W., Waterman L. J. A systematic investigation of tardive dyskinesia in inpatients. Am J Psychiatry 1979; 136: 918-922.
2. Woerner M., Kane J., Lieberman J. et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34-42.
3. Yassa R., Jeste D. V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull 1992; 18: 701-715.
4. Lund D. S. Tardive dyskinesia lawsuits on the increase. The Psychiatric Times. 1993.
5. Saltz B. L., Woerner M. G., Kane J. M. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 226: 2402-2406.
6. Lieberman J., Kane J., Woerner M. et al. Prospective study of tardive dyskinesia incidence in the elderly. Psychopharm Bull 1984; 20: 382-386.
7. Kucharski T., Smith J., Dunn D. Tardive dyskinesia and hospital discharge J Nervous Mental Dis 1980; 168.
8. Lieberman J., Kane J., Sarantakos S. Prediction of relapse in schizophrenia Arch Gen Psychiatry 1987; 44: 597-603.
9. Mehta D., Mallya A., Volavka J. Mortality of patients with tardive dyskinesia. Am J Psychiatry 1978; 135: 371-372.
10. Yassa R., Mohelsky H., Dimitry R., Schwartz G. Mortality rate in tardive dyskinesia. Am J Psychiatry 1984; 141: 1018-1019
11. Youssef H. A., Waddington J. L. Morbidity and mortality in tardive dyskinesia: associations in chronic shizophrenia. ACTA Psychiatr Scand 1987; 75: 74-77.
12. APA Task Force on Tardive Dyskinesia. APA Press, Inc., Washington, D.C., 1992.
13. Khot V., Egan M. F., Hyde T. M., Wyatt R. J. Neuroleptics and classical tardive dyskinesia. In: Lang A. E., Weiner W. J., eds. Drug-induced Movement Disorders, Mount Kisco, NY: Futura Publishing Co., 1992; pp 121-166.
14. Gerlach J., Reisby N., Randrup A. Dopamine hypersensitivity and cholinergic hypofunction in the pathophysiology of TD. Psychopharrnacologia 1974; 46: 363-369.
15. Jenner P., Maarsden C. D. Adaptive changes in brain dopamine function as a result of neuroleptic treatment. Adv Neurol 1988; 49: 417-431.
16. Burt D. R., Creese I., Snyder S. H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in the brain. Science 1977; 196: 326-328.
17. Cross A. J., Crow T. J., Ferrier I. N. et al. Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorders. J Neurol Transmission 1983; 18 (suppl.): 265-272.
18. Waddington J. L., Cross A. J., Gamble S. J., Bourne R. L. Spontaneous orofacial dyskinesia and dopaminergic function in rates after 6 months of neuroleptic treatment. Science 1983; 220: 530-532.
19. Jeste D. V., Wyatt R. J. Therapeutic stegies against tardive dyskinesia: two decades of experience. Arch Gen Psychiatry 1982; 39: 803-815.
20. Cadet J. L., Lohr J. B., Jeste D. V. Free radicals and tardive dyskinesia. Trends NeuroSci 1986; 9: 107-108.
21. Cadet J. L., Lohr J. B. Possible involvement of free radicals in neuroleptic-induced movement disorders. Ann NY Acad Sci 1989; 570: 176-185.
22. Lohr J. B., Cadet J. L., Lohr M. A., Jeste D. V., Wyatt R. J. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; 1: 913-934.
23. Lohr J. B., Cadet J. L., Lohr M. A. et al. Vitamin E in the treatment of tardive dyskinesia: The possible involvement of free radical mechanisms. Schizophrenia Bull 1988; 14: 291-296.
24. Lohr J. B., Kuczenski R., Bracha S., Moir M., Jeste D. V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28: 535-539.
25. Lohr J. B. Oxygen radicals and neuropsychiatric illness: Arch Gen Psychiatry 1992; 48: 1097-1106.
26. Lambertsen C. J. In: Mountcastle V. B., ed. Medical Physiology Vol. 2. Saint Louis: Mosby; 1980; 1722.
27. Halliwell B., Gutteridge J. M. C. Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch Biochem Biophyst 1986; 246: 501-514.
28. Halliwell B., Oxidants and the central nervous system: Some fundamental questions. Acta Neuroi Scand 1989; 126: 23-33.
29. Dobretsov G. E., Borschevskaya T. A., Petrov V. A., Vladimirov Y. A. The increase of phospholipid bilayer rigidity after lipid peroxidation. FEBS Lett 1977; 84: 125-128.
30. Bruch R. C., Thayer W. S. Differential effect of lipid peroxidation on membrane fluidity as determined by electron spin resonance probes. Biochem Biophys Acta 1983; 733: 216-222.
31. Marshansky V. N., Novgorodov S. A., Yaguzhinsky L. S. The role of lipid peroxidation in the induction of cation transport in rat liver mitochondria: The antioxidant effect of oligomycin and dicyclohexylcarbodimide. FEBS Lett 1983; 158: 27-30.
32. Scott J. A., Rabito C. A. Oxygen radicals and plasma membrane potential. Free Rad Biol Med 1988; 5: 237-246.
33. Bindoli A. Lipid peroxidation in mitochondria. Free Rad Biol Med 1988; 5: 247-261.
34. Franceschi D., Graham D., Sarasua M., Zollinger R. M. Jr. Mechanisms of oxygen free radical-induced calcium overload in endothelial cells. Surgery 1990; 108: 292-297.
35. Scott J. A. Phospholipase activity and plasma membrane homeostasis. J Theoret Biol 1984; 111: 659-665.
36. Diplock A. T., Machlin L. J., Packer L., Pryor W. A. Vitamin E: biochemistry and health implications. Ann NY Acad Sci 1989; 570.
37. Van Kujik F. J. G. M., Sevanian A., Handelman G. J., Dratz E. A. A new role for phospholipase A2: Protection of membranes from lipid peroxidation damage. Trends Biochem Sci 1987; 12: 31-34.
38. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neuro toxicology 1984; 5: 77-82.
39. Cohen G., Spina M. B. Hydrogen peroxide production in dopamine neurons: Implications for understanding Parkinson's disease. Prog Parkinson Res 1988; 119-126.
40. Weiner W. J., Nausieda P. A., Klawans H. L. Effects of chlorpromazine on central nervous system concentrations of manganese, iron, and copper. Life Sci 1977; 20: 1181-1186
41. Bird E. D., Collins G. H., Dodson M. H., Grant L. H. The effect of phenothiazine on the manganese conccentration in the basal ganglia of sub-human primates. In: Barbeau A, Burnette J-R, eds. Progress in Neuro-Genetics. Amsterdam: Excerpta Medica, 1967; 600-605.
42. Miller D. M., Buettner G. R., Aust S. D. Transition metals as catalysts of "autoxidation" reactions. Free Rad Biol Med 1990; 8: 95-108.
43. Hunter R., Blackwood W., Smith M. C., Cumings J. N. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci 1968; 7: 263-273.
44. Campbell W. G., Raskind M. A., Gordon T., Shaw C. M. Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry 1985; 142: 364-365.
45. Bartzokis G., Garber J., Oldendorf W. H., Marder S. R., Goldstein M. J. Shortened T2 of caudate in MRI study of tardive dyskinesia. Abstr Am Coll Neuropsychopharmacol 1989; 107
46. Horrobin D. F., Manku M. S., Morse-Fisher N. et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatry 1989; 25: 562-568.
47. Glen A. I. M., Glen E. M. T., Horrobin D. F. et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidencce for two diseases. Schizophrenia Res 1994; 12: 53-61.
48. Vaddadi K. S., Courtney P., Gillard C. J., Manku M. S., Horrobin D. F. A double-blind trial of essential fatty acids supplementation in patients with tardive dyskinesia. Psychiatry Res 1989; 27: 313-323
49. Pall H. S., Williams A. C., Blake D. R., Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1989; 2: 596-599.
50. Sram R. J., Binkova B., Kocisova J. et al. Antioxidants effect on alcohol, drugs and aging. In: Mendelsohn M. L., Albertini R. J., eds. Mutation and the Environment. New York: Wiley-Liss; 1990; pp 327-337
51. Lohr, J. L., Caliguiri, M. P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry In press.
52. Elkashef A. M., Ruskin P. E., Bacher N., Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990; 147: 505-506.
53. Egan M. T., Hyde T., Albers G. et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773-777.
54. Shriqui C. L., Bradwejn J., Annabel L., Jones B. D. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo controlled study. Am J Psychiatry 1992; 149: 391-393.
55. Adler L., Peselow E., Rotrosen J. et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry In Press.
56. Schmidt M., Meister P., Baumann P. Treatment of tardive dyskinesia with vitamin E. Eur Psychiatry 1991; 6: 201-207.
57. Spivak B., Schwartz B., Radwan M. et al. Alpha-tocopherol treatment for tardive dyskinesia. J Nerv Ment Dis 1992; 180: 400-401.
58. Junker D., Steigleider P., Gattaz W. F. Alpha-tocopherol in the treatment of tardive dyskinesia. Clin Neuropharm 1992; 15 (supp 1, pt b): 639B.
59. Akhtar S., Jajor T. R., Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 1993; 39: 124-126.
60. Peet M., Laugharne J., Rangarajan N., et al. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. Int Clin Psychopharm 1993; 8: 151-153.
61. Lam L. C. W., Chiu H. F. K., Hung S. F. Vitamin E in the treatment of tardive dyskinesia: A replication study. J Nerv Ment Dis 1994; 182: 113-114.
62. Dabiri L. M., Pasta D., Darby J. K. et al. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994; 151: 925-926.
63. Adler L., Peslow E., Angrist B. Vitamin E in tardive dyskinesia: Effects of longer term treatment. Am Coll Neuropsychopharmacol Abstr 1992; p. 213.